RxDoctor Payments DataLook up a doctor →

Gustavo Alva, MD

Psychiatry · Orange, CANPI 1417030222

Payments from drug & device makers

$9,785,826in general payments, 2019–2025

Across 7,899 payments — averaging $1238.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1.2M
  • Teva Pharmaceuticals USA, Inc.$1.1M
  • Livanova USA, Inc.$718K
  • Eli Lilly$668K
  • Acadia Pharmaceuticals Inc$542K
  • Otsuka America Pharmaceutical, Inc.$509K
  • plus $5M from 52 others
$50,941in research payments, 2019–2025

Across 13 payments — averaging $3918.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Avanir Pharmaceuticals, Inc.$50K
  • Eli Lilly$1K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)932$1,220,840
Teva Pharmaceuticals USA, Inc.1,161$1,133,587
Livanova USA, Inc.585$718,424
Eli Lilly13$668,111
Acadia Pharmaceuticals Inc381$541,870
Otsuka America Pharmaceutical, Inc.620$508,956
Boehringer Ingelheim40$480,591
Johnson & Johnson515$473,270
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)560$461,678
Alkermes, Inc.387$379,707
Neurocrine Biosciences, Inc.508$372,950
Axsome Therapeutics, Inc.293$370,237
Eisai Inc.215$299,691
E.r. Squibb & Sons, L.L.C.204$264,688
Vanda Pharmaceuticals Inc.261$262,040
Novartis6$239,805
Janssen Research & Development, LLC41$231,971
Sage Therapeutics, LLC53$220,294
Otsuka Pharmaceutical Development & Commercialization, Inc.42$175,565
H. Lundbeck A S58$148,896
Boehringer Ingelheim International GmbH154$117,542
Avanir Pharmaceuticals, Inc.138$111,680
Neuronetics, Inc.9$93,905
Noven Pharmaceuticals, Inc.49$54,587
Sunovion Pharmaceuticals Inc.175$47,014
Indivior Inc.74$46,931
Biogen38$39,478
Otsuka Pharmaceutical Co., Ltd.32$31,637
Luye Pharma (USA) Ltd.21$14,549
Takeda Pharmaceuticals U.S.A., Inc.35$14,200
Idorsia Pharmaceuticals US Inc20$11,146
Noven Therapeutics, LLC40$8,714
Alfasigma USA, Inc.3$4,684
Genentech, Inc.2$4,646
Boehringer Ingelheim Canada Ltd.ltee13$2,993
Neos Therapeutics, LP1$1,725
Corium, LLC9$1,550
Lundbeck LLC67$1,502
Myriad Genetic Laboratories, Inc.2$1,100
Harmony Biosciences LLC20$624
Bausch Health US, LLC35$460
Supernus Pharmaceuticals, Inc.11$393
Merck18$297
Brainsway USA Inc2$209
Adlon Therapeutics L.p.12$205
Ironshore Pharmaceuticals Inc.8$152
Biohaven Pharmaceutical Holding Company Ltd.7$120
Avadel CNS Pharmaceuticals, LLC5$118
Lilly USA, LLC4$104
Janssen Scientific Affairs, LLC4$72
Shire North American Group Inc2$65
Almatica Pharma LLC3$58
Arbor Pharmaceuticals, Inc.3$54
Braeburn Inc.2$40
Pfizer2$34
Azurity Pharmaceuticals, Inc.2$33
Sun Pharmaceutical Industries Inc.1$23
Collegium Pharmaceutical, Inc.1$18

How this compares

$9,785,826 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California →

Medicare billing

Part B allowed, 2024
$244,037
Medicare patients
327
Services billed
1,895

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other psychiatry in Orange

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →